Objective To investigate the use of laparoscopy in the resection of colorectal cancers. Methods A total of 17 cases of colorectal cancer resection had been made by laparoscopy, including 3 cases of right hemicolectomy, 3 cases of sigmoid colon cancer radical resection, 7 cases of Dixon’s procedure, 2 cases of Mile’s procedure and 2 cases of Park’s procedure. The operation was accomplished totally laparoscopically in 6 cases, while the laparoscopic-assisted and hand-assisted excision were conducted in 8 cases and 3cases, respectively. Results All the cases were cured to be discharged from the hospital. There were no deaths or complications or conversions to open surgery.The operation time was 150～240 min (mean, 190 min). The intraoperative blood loss was 20～300 ml (mean, 55 ml). The average length of postoperative hospital stay was 9.6 days. Analgesic was required in 6 cases. Follow-up for 1～6 months found no recurrence. Conclusions Laparoscopic resection of colorectal cancer is safe and feasible,with a satisfactory short-term effect.

BACKGROUND: Clinical genetics and molecular biology studies have shown that the occurrence and development of the keloid is closely related to the inheritance. However, it remians unclear if the same is ture to the hypertrophic scar. OBJECTIVE: To investigate similadties and differences of genetic alteration between the hyperplastic scar and the keloid, DESIGN, TIME AND SETTING: A contrast observational experiment was performed in Guangdong Medical College between March 2007 and December 2008.MATERIALS: Scar samples were taken from 16 patients (in-patient and out-patient) in the Department of Plastic Surgery, the Affiliated Hospital of Guangdong Medical College, with10 patients with hypertrophic scars (3 males and 7 females, 20-50 years old) and 6 patients with keloids (1 males and 5 females, 19-46 years old). METHODS: The DNA of both hyperplastic scar and keloid tissues was extracted to investigate, using comparative genomic hybridization technique, the genomic imbalance (the lose or amplification of genetic material), so as to make a comparative study on differences of the DNA copy number changes between the two. RESULTS: Neither altofrequent loss nor amplification of DNA copy number was found in any specific DNA region of hyperplastic scar tissues; as for the keloid, special DNA altofrequent loss regions were also not found, but altofrequent DNA copy number loss regions presented in 1, 16, 20 and 22 chromosomes. Comparatively, the keloid presented much higher loss rate of the DNA copy number in 1,16,20 and 22 chromosomes than the hyperplastic scar (P < 0.05).CONCLUSION: The hyperplastic scar has no conspicuous DNA copy number lose or amplification compared with the keloid, which indicates that the occurrence and development of the hyperplastic scar may not have any direct relation with the inheritance.

We conducted a randomized, open-label, parallel-controlled, multicenter trial on the use of Shuanghuanglian (SHL), a traditional Chinese patent medicine, in treating cases of COVID-19. A total of 176 patients received SHL by three doses (56 in low dose, 61 in middle dose, and 59 in high dose) in addition to standard care. The control group was composed of 59 patients who received standard therapy alone. Treatment with SHL was not associated with a difference from standard care in the time to disease recovery. Patients with 14-day SHL treatment had significantly higher rate in negative conversion of SARS-CoV-2 in nucleic acid swab tests than the patients from the control group (93.4% vs. 73.9%, P = 0.006). Analysis of chest computed tomography images showed that treatment with high-dose SHL significantly promoted absorption of inflammatory focus of pneumonia, which was evaluated by density reduction of inflammatory focus from baseline, at day 7 (mean difference (95% CI), -46.39 (-86.83 to -5.94) HU; P = 0.025) and day 14 (mean difference (95% CI), -74.21 (-133.35 to -15.08) HU; P = 0.014). No serious adverse events occurred in the SHL groups. This study illustrated that SHL in combination with standard care was safe and partially effective for the treatment of COVID-19.
COVID-19 ; Humans ; Medicine, Chinese Traditional ; Research ; SARS-CoV-2 ; Treatment Outcome